Stem11 score: towards rapid clinical prognostication for acute myeloid leukemia

Acute myeloid leukemia (AML) is an aggressive form of myeloid malignancy with high relapse and poor survival rates.Despite recent advances in genomics-based risk classification, accurate prediction of patient outcomes remains a challenge, posing the need for complementary molecular information to enable precise treatment stratification.In the current study, we assess the prognostic value of the recently developed 11-gene Stem11 signature in a uniformly treated cohort of 107 de novo AML patients and show that Stem11 classification stratifies overall survival and response to allogeneic hematopoietic cell transplantation across the European LeukemiaNet risk groups.We further develop a NanoString-based Stem11 scoring platform and validate its high concordance with RNA-sequencing-based scoring and its retained prognostic power to identify the most refractory AML subgroup.With its rapid turnaround time and standardized built-in analysis pipeline, our NanoString-based Stem11 scoring panel represents a faster yet reliable alternative to RNA-sequencing, providing preclinical proof of concept for Stem11-based clinical decision support.